Annual Total Liabilities
$363.11 M
-$41.66 M-10.29%
December 31, 2023
Summary
- As of February 7, 2025, FHTX annual total liabilities is $363.11 million, with the most recent change of -$41.66 million (-10.29%) on December 31, 2023.
- During the last 3 years, FHTX annual total liabilities has risen by +$253.70 million (+231.89%).
- FHTX annual total liabilities is now -14.14% below its all-time high of $422.90 million, reached on December 31, 2021.
Performance
FHTX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$336.66 M
-$6.25 M-1.82%
September 30, 2024
Summary
- As of February 7, 2025, FHTX quarterly total liabilities is $336.66 million, with the most recent change of -$6.25 million (-1.82%) on September 30, 2024.
- Over the past year, FHTX quarterly total liabilities has dropped by -$34.15 million (-9.21%).
- FHTX quarterly total liabilities is now -20.39% below its all-time high of $422.90 million, reached on December 31, 2021.
Performance
FHTX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
FHTX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -10.3% | -9.2% |
| 3 y3 years | +231.9% | -15.3% |
| 5 y5 years | +341.0% | -15.3% |
FHTX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -14.1% | at low | -20.4% | at low |
| 5 y | 5-year | -14.1% | +231.9% | -20.4% | +341.8% |
| alltime | all time | -14.1% | +341.0% | -20.4% | +341.8% |
Foghorn Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $336.66 M(-1.8%) |
| Jun 2024 | - | $342.91 M(-2.7%) |
| Mar 2024 | - | $352.49 M(-2.9%) |
| Dec 2023 | $363.11 M(-10.3%) | $363.11 M(-2.1%) |
| Sep 2023 | - | $370.81 M(-4.7%) |
| Jun 2023 | - | $388.93 M(-2.1%) |
| Mar 2023 | - | $397.47 M(-1.8%) |
| Dec 2022 | $404.77 M | $404.77 M(-1.2%) |
| Sep 2022 | - | $409.61 M(+0.1%) |
| Jun 2022 | - | $409.27 M(-1.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $415.90 M(-1.7%) |
| Dec 2021 | $422.90 M(+286.5%) | $422.90 M(+302.4%) |
| Sep 2021 | - | $105.09 M(+0.7%) |
| Jun 2021 | - | $104.34 M(-0.4%) |
| Mar 2021 | - | $104.72 M(-4.3%) |
| Dec 2020 | $109.41 M(-0.9%) | $109.41 M(-60.3%) |
| Sep 2020 | - | $275.75 M(+261.9%) |
| Jun 2020 | - | $76.20 M(-31.0%) |
| Dec 2019 | $110.36 M(+34.0%) | $110.36 M |
| Dec 2018 | $82.33 M | - |
FAQ
- What is Foghorn Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Foghorn Therapeutics?
- What is Foghorn Therapeutics annual total liabilities year-on-year change?
- What is Foghorn Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Foghorn Therapeutics?
- What is Foghorn Therapeutics quarterly total liabilities year-on-year change?
What is Foghorn Therapeutics annual total liabilities?
The current annual total liabilities of FHTX is $363.11 M
What is the all time high annual total liabilities for Foghorn Therapeutics?
Foghorn Therapeutics all-time high annual total liabilities is $422.90 M
What is Foghorn Therapeutics annual total liabilities year-on-year change?
Over the past year, FHTX annual total liabilities has changed by -$41.66 M (-10.29%)
What is Foghorn Therapeutics quarterly total liabilities?
The current quarterly total liabilities of FHTX is $336.66 M
What is the all time high quarterly total liabilities for Foghorn Therapeutics?
Foghorn Therapeutics all-time high quarterly total liabilities is $422.90 M
What is Foghorn Therapeutics quarterly total liabilities year-on-year change?
Over the past year, FHTX quarterly total liabilities has changed by -$34.15 M (-9.21%)